Pivotal trials and novel combinations have started, but four programmes seem to have been discontinued.
ApexOnco Front Page
Recent articles
Varseta-M efficacy wanes, but more than justifies a pivotal trial.
For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.
A year after paying $55m to license Biotheus’s PD-L1/VEGF, BioNTech is going all in for $800m.
First-gen drugs feature in BCL-2 combos, while Jaypirca and BTK degraders apply extra pressure.
The company’s CD38 x CD28 MAb is among recent clinical trial entrants.
Response rates in relapsed NPM1-mutant AML look slightly worse than before, but QTc prolongation could be the real worry.
AbbVie looks to justify its faith in TeneoOne, and Bristol its phase 3 move with BMS-986393.
